Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LacTEST study in celiac disease and intestinal barrier integrity
2026-525518-70-00Phase 4Authorised
- Sponsor
- Venter Pharma
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Gaxilose in celiac disease, sponsored by Venter Pharma. Primary endpoints: Change in Marsh-Oberhuber classification, Change in direct intestinal lactase activity and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
Gaxilose
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2026-525518-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525518-70-00.